It’s that time of the week again to see who has been shifting jobs and upping ladders in the outsourcing world and we begin this week with news from Aptuit.
Kurt Dinkelacker - previously Executive Vice President and CFO at Retrievex - has been named Executive Vice President and Chief Financial Officer, and Kevin Duffield (pictured) – with over 25 years experience in pharmaceutical contract manufacturing services - has been promoted to Vice President, Sales and Business Development.
“These two proven pros are valuable additions to our team, ready to implement a strategy that will help steer Aptuit to its position as a market-leading provider of early to mid-phase integrated drug discovery and development,” said Stuart Needleman, Aptuit’s President and COO.
And you can read here about the ex-Aptuit employee who is currently serving jail time for trial data manipulation.
Primate Research Company SNBL USA has entered into a consulting agreement with Dr. Pritam Sahota of Global ToxPath in order to augment its pathology services on an ongoing basis.
Sahota has had a number of roles before Global ToxPath, including being responsible for anatomic, clinical, investigative and discovery pathology at Drug Giant Novartis.
Dr. Stewart Jacobson, SNBL USA director of pathology services said: “We are very excited to have Pritam working with us to provide additional support with client study designs and program development, peer reviews and general pathologic expertise.”
And late last year the company received an FDA ‘close-out’ letter ending issues at its animal laboratory in Washington State. Read about it here.
Matt Murphy, with 17 years of experience with AstraZeneca, has been promoted to Vice President of pharma brand-sales maximising service company Delta Point.
"Our focus at Delta Point is to exceed our customer's expectations—and Matt has done an exemplary job in doing just that since he joined Delta Point in 2011,” said Delta Point's CEO and founder Jerry Acuff.
Results Healthcare – a company which provides business advice and lead advisory corporate finance expertise to the healthcare industries - has announced that Brigette de Lima will be joining the company as a Senior Analyst.
De Lima worked as an Equity Research Analyst at Merrill Lynch between 2006 and 2012 where she covered European Biotechnology, Mid cap pharma, Diagnostics and Life Science companies.
Results Healthcare Managing Director Kevin Bottomley said of de Lima: “Her solid scientific background combined with strong financial forecasting and modelling, company analysis and equity valuation skills, will make her a key resource for our global client base.”